Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy
NCT07227909Phase 2Not yet recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2026
- Primary completion
- Jan 2029
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of psilocybin in chemotherapy-induced peripheral neuropathy (CIPN), sponsored by University of Texas MD Anderson Cancer Center. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
psilocybin
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT07227909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07227909.